Literature DB >> 4040550

High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study.

A Veronesi, V Zagonel, U Tirelli, E Galligioni, S Tumolo, L Barzan, M Lorenzini, R Comoretto, E Grigoletto.   

Abstract

From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dose (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4040550     DOI： 10.1200/JCO.1985.3.8.1105

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  10 in total

Review 1.  Head and neck cancer: guidelines for chemotherapy.

Authors:  G Catimel
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 2.  Chemotherapeutic management of head and neck cancer.

Authors:  M Al-Sarraf
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.

Authors:  Ambika Parmar; Michaelina Macluskey; Niall Mc Goldrick; David I Conway; Anne-Marie Glenny; Janet E Clarkson; Helen V Worthington; Kelvin Kw Chan
Journal:  Cochrane Database Syst Rev       Date:  2021-12-20

4.  Effect of Exercise Training on Exercise Tolerance and Level of Oxidative Stress for Head and Neck Cancer Patients Following Chemotherapy.

Authors:  Chia-Jui Yen; Ching-Hsia Hung; Wei-Ming Tsai; Hui-Ching Cheng; Hsin-Lun Yang; Yan-Jhen Lu; Kun-Ling Tsai
Journal:  Front Oncol       Date:  2020-08-18       Impact factor: 6.244

5.  Management of unresectable head and neck cancers - a retrospective analysis at a rural medical college of India.

Authors:  Aloke Ghosh Dastidar; Somnath Saha; Abhishekh Srivastava; Debdulal Chakroborty; Balaram Sardar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-06-04

6.  Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.

Authors:  R Hitt; A Jimeno; M Rodríguez-Pinilla; J L Rodríguez-Peralto; J M Millán; A López-Martín; A Brandariz; C Peña; H Cortés-Funes
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

7.  Sensitizing thermochemotherapy with a PARP1-inhibitor.

Authors:  Arlene L Oei; Lianne E M Vriend; Caspar M van Leeuwen; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; Roland Kanaar; H Petra Kok; Przemek M Krawczyk; Nicolaas A P Franken
Journal:  Oncotarget       Date:  2017-03-07

Review 8.  Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy.

Authors:  Sandro V Porceddu; Florian Scotté; Matti Aapro; Satu Salmio; Ana Castro; Vincent Launay-Vacher; Lisa Licitra
Journal:  Front Oncol       Date:  2020-01-22       Impact factor: 6.244

9.  Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.

Authors:  Dongbin Ahn; Gil Joon Lee; Jin Ho Sohn; Jeong Eun Lee
Journal:  Cancer Med       Date:  2020-10-19       Impact factor: 4.452

10.  Laryngeal preservation in stage III/IV resectable laryngo-hypopharyngeal squamous cell carcinoma following concurrent chemoradiotherapy with capecitabine/cisplatin.

Authors:  Dongbin Ahn; Jae Hyug Kim; Jin Ho Sohn; Chang-Min Sin; Jeong Eun Lee
Journal:  Mol Clin Oncol       Date:  2013-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.